Taking stock of the drug industry, from the lab to the medicine chestSeptember 4, 2025Check out STAT+Sponsored By By Ed SilvermanPharmalot Columnist, Senior Writer Andrew Harnik/Getty Images STAT+ | In major shift, FDA to start releasing rejection letters shortly after they're issued The letters, which detail the FDA's concerns about a product, have generally not been made public before, creating transparency concerns. By Andrew Joseph and Ed Silverman STAT+ | Trump administration confirms plan for PEPFAR to distribute Gilead's new HIV prevention drug The deal is a bridge to a longer-term solution in which Gilead licensed its drug to generic makers but they won't have product for two years. By Ed Silverman and Jason Mast STAT+ | Sanofi shares drop after disappointing trial results The company is working to develop medicines for immunological and inflammatory conditions, building on the success it's had with Dupixent. By Andrew Joseph Courtesy Atlas Venture STAT+ | Biotech VC raises $400 million 'opportunity' fund in sign of possible industry rebound This is the third time Atlas, a biotech VC firm, has raised an opportunity fund. It last raised $300 million for one in 2021. By Allison DeAngelis STAT+ | Is biotech back? Don't jinx it, but the signs are encouraging In this edition of "Adam's Biotech Scorecard," Adam sees signs of hope for the industry, even if it's too early to declare a biotech recovery. By Adam Feuerstein More around STATCheck out more exclusive coverage with a STAT+ subscriptionRead premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.Enjoying Pharmalot? Tell us about your experienceContinue reading the latest health & science news with the STAT appDownload on the App Store or get it on Google Play STAT, 1 Exchange Place, Boston, MA©2025, All Rights Reserved.I no longer wish to receive STAT emailsUpdate Newsletter Preferences • Contact Us • Advertise with Us • View in Browser
No comments